Literature DB >> 27587466

Developing EZH2-Targeted Therapy for Lung Cancer.

Arthur E Frankel1, Xin Liu2, John D Minna3.   

Abstract

Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27587466      PMCID： PMC5012289          DOI： 10.1158/2159-8290.CD-16-0800

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  13 in total

1.  Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.

Authors:  Lianying Jiao; Xin Liu
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

2.  Enzyme-dependent lysine deprotonation in EZH2 catalysis.

Authors:  D Randal Kipp; Christopher M Quinn; Pascal D Fortin
Journal:  Biochemistry       Date:  2013-09-18       Impact factor: 3.162

3.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

Authors:  Wei Qi; HoMan Chan; Lin Teng; Ling Li; Shannon Chuai; Ruipeng Zhang; Jue Zeng; Min Li; Hong Fan; Ying Lin; Justin Gu; Ophelia Ardayfio; Ji-Hu Zhang; Xiaoxia Yan; Jialuo Fang; Yuan Mi; Man Zhang; Tao Zhou; Grace Feng; Zijun Chen; Guobin Li; Teddy Yang; Kehao Zhao; Xianghui Liu; Zhengtian Yu; Chris X Lu; Peter Atadja; En Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

4.  The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.

Authors:  Kevin W Kuntz; John E Campbell; Heike Keilhack; Roy M Pollock; Sarah K Knutson; Margaret Porter-Scott; Victoria M Richon; Chris J Sneeringer; Tim J Wigle; Christina J Allain; Christina R Majer; Mikel P Moyer; Robert A Copeland; Richard Chesworth
Journal:  J Med Chem       Date:  2016-01-27       Impact factor: 7.446

Review 5.  Targeting EZH2 in cancer.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Nat Med       Date:  2016-02       Impact factor: 53.440

Review 6.  Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.

Authors:  Gerard L Brien; Daria G Valerio; Scott A Armstrong
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

7.  Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

Authors:  Haikuo Zhang; Jun Qi; Jaime M Reyes; Lewyn Li; Prakash K Rao; Fugen Li; Charles Y Lin; Jennifer A Perry; Matthew A Lawlor; Alexander Federation; Thomas De Raedt; Yvonne Y Li; Yan Liu; Melissa A Duarte; Yanxi Zhang; Grit S Herter-Sprie; Eiki Kikuchi; Julian Carretero; Charles M Perou; Jacob B Reibel; Joshiawa Paulk; Roderick T Bronson; Hideo Watanabe; Christine Fillmore Brainson; Carla F Kim; Peter S Hammerman; Myles Brown; Karen Cichowski; Henry Long; James E Bradner; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2016-06-16       Impact factor: 39.397

8.  Selective inhibitors of protein methyltransferases.

Authors:  H Ümit Kaniskan; Kyle D Konze; Jian Jin
Journal:  J Med Chem       Date:  2014-12-02       Impact factor: 7.446

9.  Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.

Authors:  Alexei Brooun; Ketan S Gajiwala; Ya-Li Deng; Wei Liu; Ben Bolaños; Patrick Bingham; You-Ai He; Wade Diehl; Nicole Grable; Pei-Pei Kung; Scott Sutton; Karen A Maegley; Xiu Yu; Al E Stewart
Journal:  Nat Commun       Date:  2016-04-28       Impact factor: 14.919

Review 10.  Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.

Authors:  Ludovica Morera; Michael Lübbert; Manfred Jung
Journal:  Clin Epigenetics       Date:  2016-05-24       Impact factor: 6.551
View more
  14 in total

1.  HMGA1 induces EZH2 overexpression in human B-cell lymphomas.

Authors:  Marco De Martino; Pedro Nicolau-Neto; Luis Felipe Ribeiro Pinto; Alexandra Traverse-Glehen; Emmanuel Bachy; Vincenzo Gigantino; Rossella De Cecio; Francesco Bertoni; Paolo Chieffi; Alfredo Fusco; Francesco Esposito
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 2.  Small-cell lung cancer: what we know, what we need to know and the path forward.

Authors:  Adi F Gazdar; Paul A Bunn; John D Minna
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

Review 3.  Polycomb Repressor Complex 2 in Genomic Instability and Cancer.

Authors:  Zoe Veneti; Kalliopi K Gkouskou; Aristides G Eliopoulos
Journal:  Int J Mol Sci       Date:  2017-07-30       Impact factor: 5.923

Review 4.  Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.

Authors:  Tengrui Zhang; Yueqing Gong; Hui Meng; Chen Li; Lixiang Xue
Journal:  Clin Epigenetics       Date:  2020-05-24       Impact factor: 6.551

5.  EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer.

Authors:  Lilong Xia; Xinhai Zhu; Lei Zhang; Yanhui Xu; Guoping Chen; Jing Luo
Journal:  Biotechnol Appl Biochem       Date:  2020-04-16       Impact factor: 2.431

6.  Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.

Authors:  Kui Fan; Chuan-Long Zhang; Yuan-Fu Qi; Xin Dai; Yoann Birling; Zhao-Feng Tan; Fang Cao
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

7.  Sodium Valproate Inhibits Small Cell Lung Cancer Tumor Growth on the Chicken Embryo Chorioallantoic Membrane and Reduces the p53 and EZH2 Expression.

Authors:  Lina Šlekienė; Donatas Stakišaitis; Ingrida Balnytė; Angelija Valančiūtė
Journal:  Dose Response       Date:  2018-04-26       Impact factor: 2.658

8.  Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma.

Authors:  Yu Zheng; Baihui Li; Jian Wang; Yanjuan Xiong; Kaiyuan Wang; Ying Qi; Houfang Sun; Lei Wu; Lili Yang
Journal:  Clin Epigenetics       Date:  2018-10-22       Impact factor: 6.551

Review 9.  Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges.

Authors:  Yuchen Chen; Xinran Liu; Yangkai Li; Chuntao Quan; Ling Zheng; Kun Huang
Journal:  Comput Struct Biotechnol J       Date:  2018-06-20       Impact factor: 7.271

Review 10.  Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance.

Authors:  Tongyan Liu; Chencheng Han; Panqi Fang; Hongyu Zhu; Siwei Wang; Zhifei Ma; Quanli Zhang; Wenjia Xia; Jie Wang; Lin Xu; Rong Yin
Journal:  Cell Mol Life Sci       Date:  2020-11-10       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.